Tumor Drug Penetration Measurements Could Be the Neglected Piece of the Personalized Cancer Treatment Puzzle.
Tumor Drug Penetration Measurements Could Be the Neglected Piece of the Personalized Cancer Treatment Puzzle.
复制标题
DOI：
10.1002/cpt.1211
复制
发表时间：
2019-07
影响因子：
6.7
通讯作者：
Gebhart G
中科院分区：
文献类型：
--
作者：
Bartelink IH;Jones EF;Shahidi-Latham SK;Lee PRE;Zheng Y;Vicini P;van 't Veer L;Wolf D;Iagaru A;Kroetz DL;Prideaux B;Cilliers C;Thurber GM;Wimana Z;Gebhart G
精确医学旨在使用患者基因组、表观基因组、特定药物剂量和其他数据来定义可能导致改善治疗结果的疾病模式。基于肿瘤药物渗透的个性化给药方案在这一方法中可以发挥关键作用。测量肿瘤药物渗透的最新技术侧重于全身暴露、组织渗透、细胞或分子参与以及药理活性的表达。在电子计算机方法中使用，这些信息可以被整合起来，以弥合治疗方案和药物与临床结果之间的联系。描述了这些方法，并讨论了未来的挑战。这篇综述有许多例子支持，展示了这些技术的结合如何在肿瘤组织水平、靶点结合和下游药理学上提供关于药物可获得性的增强的患者特定信息。我们对如何应用肿瘤药物渗透测量的愿景为临床实施精确剂量提供了路线图。
Precision medicine aims to use patient genomic, epigenomic, specific drug dose, and other data to define disease patterns that may potentially lead to an improved treatment outcome. Personalized dosing regimens based on tumor drug penetration can play a critical role in this approach. State‐of‐the‐art techniques to measure tumor drug penetration focus on systemic exposure, tissue penetration, cellular or molecular engagement, and expression of pharmacological activity. Using in silico methods, this information can be integrated to bridge the gap between the therapeutic regimen and the pharmacological link with clinical outcome. These methodologies are described, and challenges ahead are discussed. Supported by many examples, this review shows how the combination of these techniques provides enhanced patient‐specific information on drug accessibility at the tumor tissue level, target binding, and downstream pharmacology. Our vision of how to apply tumor drug penetration measurements offers a roadmap for the clinical implementation of precision dosing.
登录
查看更多内容
影响因子：
4.6
作者：
Checkley, Stephen;MacCallum, Linda;Bendtsen, Claus
通讯作者：
Bendtsen, Claus
影响因子：
--
作者：
Gay, Laura;Baker, Ann-Marie;Graham, Trevor A
通讯作者：
Graham, Trevor A
影响因子：
82.9
作者：
通讯作者：
--
DOI：
10.1186/s13058-017-0896-4
发表时间：
2017-09-11
期刊：
Breast cancer research : BCR
影响因子：
--
作者：
Bartelink IH;Prideaux B;Krings G;Wilmes L;Lee PRE;Bo P;Hann B;Coppé JP;Heditsian D;Swigart-Brown L;Jones EF;Magnitsky S;Keizer RJ;de Vries N;Rosing H;Pawlowska N;Thomas S;Dhawan M;Aggarwal R;Munster PN;Esserman LJ;Ruan W;Wu AHB;Yee D;Dartois V;Savic RM;Wolf DM;van 't Veer L
通讯作者：
van 't Veer L
影响因子：
51.1
作者：
Bray, Freddie;Jemal, Ahmedin;Forman, David
通讯作者：
Forman, David